---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-044309"
form_type: "8-K"
ticker: "GTBP"
cik: "0000109657"
company_name: "GT Biopharma, Inc."
filed_at: "2026-09-25T20:10:15+00:00"
generated_at: "2026-10-12T13:22:20.616166+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# GT Biopharma regains Nasdaq $1.00 minimum bid price compliance as of September 22, 2026

## Summary
- Nasdaq notified GT Biopharma on September 22, 2026 that it regained compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).
- Common stock (GTBP) closed above $1.00 per share for at least ten consecutive business days, satisfying Nasdaq's standard for regaining compliance.
- Deficiency began with a November 20, 2025 Nasdaq staff letter citing 30 consecutive business days below $1.00; Nasdaq granted a 180-day extension on May 20, 2026 running to November 16, 2026.
- The notice removes the pending delisting risk that had been outstanding for roughly ten months; no capital raise, reverse split, or other remedial transaction is disclosed.

## SEC filing metadata
- accession: 0001493152-26-044309
- form_type: 8-K
- ticker: GTBP
- cik: 0000109657
- company_name: GT Biopharma, Inc.
- filed_at: 2026-09-25T20:10:15+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/109657/000149315226044309/0001493152-26-044309-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/109657/000149315226044309/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-044309
- JSON: https://secwatch.observer/filing/0001493152-26-044309.json
- Plain text: https://secwatch.observer/filing/0001493152-26-044309.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.